This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Processes are provided that include additive compounds suitable for detecting the activity of an enzyme such as a lysosomal storage enzyme where the additive is a salt of oleic acid. Inclusion of a salt of oleic acid unexpectedly improves enzyme activity and reproducibility.

The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

The current invention concerns an in vitro method for (i) measuring, predicting, diagnosing, prognosing and/or monitoring chronic mental stress or for (ii) determining whether a subject is in need of therapeutic or prophylactic treatment of a chronic mental stress in a subject, comprising detecting at least three biomarkers independently selected at least three, different groups of biomarkers selected from a group of immune function biomarkers, a group of iron metabolism biomarkers, a group of metabolism biomarkers, a group of steroid hormone biomarkers, a group of sympathetic adrenal medullary axis biomarkers, and optionally a group of neurotransmitter biomarkers, in a sample obtained from said subject, and kits and computer programs for use in such methods.

Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.